Home  »  Trending   »  We Analyzed the Future Direction of Deciphera Phar...

We Analyzed the Future Direction of Deciphera Pharmaceuticals Inc. (DCPH), Here is What We Found

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) went down by -2.99% from its latest closing price compared to the recent 1-year high of $22.76. The company’s stock price has collected -16.98% of loss in the last five trading sessions.

Is It Worth Investing in Deciphera Pharmaceuticals Inc. (NASDAQ :DCPH) Right Now?

Plus, the 36-month beta value for DCPH is at 0.71. Opinions of the stock are interesting as 6 analysts out of 11 who provided ratings for Deciphera Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 4 rated it as “hold,” and 1 as “sell.”

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


The average price from analysts is $20.09, which is $3.37 above the current price. DCPH currently public float of 49.05M and currently shorts hold a 14.64% ratio of that float. Today, the average trading volume of DCPH was 674.66K shares.

DCPH’s Market Performance

DCPH stocks went down by -16.98% for the week, with a monthly jump of 15.68% and a quarterly performance of 8.44%, while its annual performance rate touched 119.02%. The volatility ratio for the week stands at 7.59% while the volatility levels for the past 30 days are set at 7.12% for Deciphera Pharmaceuticals Inc. The simple moving average for the period of the last 20 days is -4.75% for DCPH stocks with a simple moving average of 20.74% for the last 200 days.

Analysts’ Opinion of DCPH

Many brokerage firms have already submitted their reports for DCPH stocks, with Guggenheim repeating the rating for DCPH by listing it as a “Buy.” The predicted price for DCPH in the upcoming period, according to Guggenheim is $22 based on the research report published on January 04th of the current year 2023.

Cowen, on the other hand, stated in their research note that they expect to see DCPH reach a price target of $25. The rating they have provided for DCPH stocks is “Outperform” according to the report published on August 29th, 2022.

JMP Securities gave a rating of “Mkt Outperform” to DCPH, setting the target price at $23 in the report published on August 05th of the previous year.

DCPH Trading at 5.99% from the 50-Day Moving Average

After a stumble in the market that brought DCPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.57% of loss for the given period.

Volatility was left at 7.12%, however, over the last 30 days, the volatility rate increased by 7.59%, as shares surge +12.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.91% upper at present.

During the last 5 trading sessions, DCPH fell by -16.98%, which changed the moving average for the period of 200-days by +79.94% in comparison to the 20-day moving average, which settled at $18.84. In addition, Deciphera Pharmaceuticals Inc. saw 8.91% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at DCPH starting from Sherman Matthew L, who sale 2,403 shares at the price of $21.24 back on Jan 17. After this action, Sherman Matthew L now owns 72,628 shares of Deciphera Pharmaceuticals Inc., valued at $51,043 using the latest closing price.

Pitman Jama, the of Deciphera Pharmaceuticals Inc., sale 1,603 shares at $21.24 during a trade that took place back on Jan 17, which means that Pitman Jama is holding 35,058 shares at $34,050 based on the most recent closing price.

Stock Fundamentals for DCPH

Current profitability levels for the company are sitting at:

  • -284.85 for the present operating margin
  • +90.23 for the gross margin

The net margin for Deciphera Pharmaceuticals Inc. stands at -311.98. Equity return is now at value -65.40, with -49.30 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 3.50.

Is SSR Mining Inc. (SSRM) a Keeper?

SSR Mining Inc. (NASDAQ:SSRM) went down by -3.03% from its latest closing price compared to the recent 1-year high of $24.58. The company’s stock price